Andropause vs. perimenopause: what TRT content gets wrong

What's this video probably claiming?

Based on the hashtag pairing of #andropause and #perimenopause alongside #decentermen, this creator is almost certainly drawing a parallel between male hormonal decline and female perimenopause, likely arguing that men go through a version of the same thing and deserve sympathy, treatment, or both. These videos typically frame testosterone decline as a dramatic, underdiagnosed condition that mirrors the female menopause experience. Some go further, suggesting TRT is a straightforward fix that men are unfairly denied, or that recognizing andropause validates certain male behavioral or emotional shifts. The #decentermen hashtag suggests a tone of advocacy, possibly positioning hormone optimization as part of being a functional, emotionally present partner. That framing is partly useful and partly a stretch, and the distinction matters clinically.

What does the science actually show?

Male testosterone does decline with age, roughly 1 to 2 percent per year after age 30, according to Harman et al. (2001, Journal of Clinical Endocrinology and Metabolism), who tracked 890 men over 10 years. But the term "andropause" is contested. Unlike female menopause, which is a defined biological event involving ovarian follicle depletion, male hormonal decline is gradual, variable, and not universal. The Endocrine Society's 2018 clinical guidelines explicitly state that hypogonadism requires both low serum testosterone (generally below 300 ng/dL on two morning measurements) and symptoms, not just one or the other. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine), the largest TRT cardiovascular safety trial to date with 5,246 men, found no increased major adverse cardiac events with testosterone gel over roughly 33 months, which resolved some long-standing safety debates. That said, TRT is not a lifestyle supplement for men with age-related low-normal testosterone who are otherwise healthy.

Where does the social media noise diverge from clinical reality?

The biggest distortion in andropause content is conflating normal aging with a diagnosable deficiency. A man feeling tired, less motivated, or gaining belly fat at 45 may simply be experiencing the predictable consequences of poor sleep, elevated cortisol, or metabolic changes, not hypogonadism. TRT content on TikTok tends to skip that differential entirely. Perimenopause comparisons are emotionally resonant but biologically imprecise. Female perimenopause involves dramatic, measurable estrogen fluctuation within months; male testosterone decline is slow and often subclinical. The comparison can be useful for normalizing men seeking care, but it risks encouraging men with normal testosterone to seek unnecessary treatment. Bhasin et al. (2010, New England Journal of Medicine) showed that testosterone doses that raised levels above 500 ng/dL did improve lean mass and sexual function, but benefits were modest and dose-dependent, and men in the normal range were not the study population.

What should you actually know?

If you're a man experiencing symptoms that might fit hypogonadism, the first step is actual lab work, not a TikTok diagnosis. Two early morning total testosterone measurements, plus LH, FSH, and ideally free testosterone via equilibrium dialysis, are the baseline. If your total testosterone is consistently below 300 ng/dL with matching symptoms, that is a conversation worth having with a licensed clinician. TRT is a regulated medical treatment, not a wellness trend. It requires monitoring, including hematocrit checks (polycythemia is a real risk, with hematocrit exceeding 54 percent being a standard threshold for dose adjustment), PSA surveillance, and periodic reassessment of fertility goals since exogenous testosterone suppresses sperm production. The perimenopause parallel in this video may resonate emotionally, but it should not substitute for proper diagnosis. Hormone optimization content can open doors to legitimate care. It can also funnel healthy men into unnecessary treatment. The difference comes down to whether a real clinician is involved.